- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941336
Acute Effects of Myofascial Release on Squat Jump Performance
Investigation of the Acute Effects of Myofascial Release Technique Applied to Lower Extremity Muscles on Squat Jump Performance and Lower Extremity Kinematics: A Randomized Controlled Trial
This randomized controlled trial will investigate the acute (immediate) effects of a single session of manual myofascial release applied to lower extremity muscles on squat jump height and lower extremity joint kinematics in healthy young adults aged 18-40 years. Sixty volunteers will be randomly assigned to a myofascial release group or a control (rest) group. After a standardized warm-up, all participants will perform three maximal squat jumps. The intervention group will then receive standardized bilateral manual myofascial release to predetermined lower extremity muscle groups, while the control group will rest for an equivalent period. Squat jump testing will then be repeated under identical conditions. Jump height will be measured with the validated smartphone application My Jump 2, and hip, knee and ankle kinematics during the jump will be recorded with a Microsoft Kinect-based markerless motion analysis system.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Squat jump (SJ) is a widely used field test of lower extremity explosive strength that isolates concentric force production by eliminating the countermovement. Myofascial release (MFR) is commonly used in physiotherapy and sports settings to improve range of motion and flexibility; however, its acute effects on strength, power and explosive performance vary according to technique, duration and targeted muscle group, and the effects of standardized manual MFR applied to specific lower extremity regions on jump performance and joint kinematics have not been adequately investigated.
Design: Two-arm, parallel-group, randomized controlled trial with a pre-test/post-test design. Participants will be randomly allocated 1:1 to the MFR group or the control group using a computer-generated randomization list. The study will be conducted at the Üsküdar University Physiotherapy and Rehabilitation Application and Research Center (ÜSTFİZYOTEM), Istanbul, Türkiye.
Procedures: After informed consent, demographic and descriptive data (age, sex, height, body mass, dominant lower limb, physical activity habits, injury and surgical history) will be recorded. All participants will receive an explanation of the SJ technique and a standardized warm-up. Baseline testing: participants will perform three maximal vertical squat jumps from a predetermined knee-flexion starting position with hands on hips and without countermovement, with adequate rest between trials. Jump height (cm) will be measured using the My Jump 2 smartphone application from high-speed video (take-off and landing frames). Simultaneously, hip, knee and ankle joint motion during the jump will be recorded with a Microsoft Kinect-based motion analysis system. Intervention: the MFR group will receive standardized bilateral manual myofascial release to four lower extremity muscle groups (gluteal, quadriceps, hamstring and triceps surae) using a sustained cross-hand release technique (90 seconds per muscle group per limb; total application time 12 minutes), with pressure direction, participant position and application region standardized across participants. The control group will rest quietly for an equivalent duration and will receive no manual therapy. Post-testing: immediately after the intervention or rest period, the SJ test will be repeated under identical conditions (same device, technique, position and environment).
Outcomes: The primary outcome is the change in squat jump height (cm, My Jump 2) from pre- to post-intervention. Secondary outcomes are sagittal-plane hip, knee and ankle kinematics during the squat jump obtained from the Kinect-based system: peak flexion (hip, knee) and peak dorsiflexion (ankle) angles in the starting squat position, joint angles at take-off, joint range of motion during propulsion (take-off angle minus starting angle) and, as exploratory variables, peak joint angular extension velocities during the propulsive phase.
Sample size: 60 participants (30 per group). Analysis: Normality will be assessed with the Shapiro-Wilk test, histograms and Q-Q plots. Descriptive data will be presented as mean ± SD or median (IQR) and counts (%). The primary outcome will be analyzed with a two-way mixed-design repeated-measures ANOVA (group × time), with the group × time interaction as the main indicator of the acute effect of MFR; post-hoc pairwise comparisons with correction for multiple comparisons will be performed when appropriate. Non-parametric alternatives will be used if assumptions are violated. Secondary kinematic variables will be analyzed in the same way. Significance will be set at p < 0.05; effect sizes and 95% confidence intervals will be reported.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ömer Şevgin
- Phone Number: +905069787535
- Email: omer.sevgin@uskudar.edu.tr
Study Locations
-
-
-
Istanbul, Turkey (Türkiye)
- Uskudar university
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-40 years
- Volunteering to participate and signing the informed consent form
- Ability to perform the squat jump test independently and safely
- No pain or functional limitation markedly restricting active lower extremity movement or jump performance
- Ability to understand and follow verbal instructions during the study
Exclusion Criteria:
- Lower extremity or lumbar surgery within the last 6 months
- Muscle, tendon, ligament or joint injury of the lower extremity within the last 3 months that may affect jump performance
- Acute lower extremity or lumbar pain at the time of assessment
- Neurological, musculoskeletal or cardiovascular disease that may affect jump performance or safe exercise
- Open wound, active infection, serious dermatological condition or any other contraindication in the myofascial release application area
- Development of pain, dizziness, dyspnea or any symptom preventing safe continuation during testing or application
- Failure to complete the study protocol or voluntary withdrawal
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Myofascial release group
Standardized warm-up and baseline squat jump testing, followed by a single session of standardized bilateral manual myofascial release applied to predetermined lower extremity muscle groups, followed by post-intervention squat jump testing under identical conditions. |
A single session of manual myofascial release applied bilaterally by a physiotherapist to four lower extremity muscle groups: gluteal muscles (prone), quadriceps (supine), hamstrings (prone) and triceps surae (prone). Technique: sustained cross-hand myofascial release with slow, low-load pressure applied in the direction of tissue restriction until a tissue release is felt, held for 90 seconds per muscle group per limb (4 muscle groups × 2 limbs × 90 s = 12 minutes total), without oil or lubricant. Order of application (gluteal → hamstring → triceps surae → quadriceps), participant position, direction of pressure and duration are standardized for all participants. Applied immediately after baseline squat jump testing; post-testing follows within 2 minutes after the application.
Other Names:
|
|
No Intervention: Control (rest) group
Standardized warm-up and baseline squat jump testing, followed by 12 minutes of quiet seated rest (equivalent to the myofascial release application time), followed by post-test squat jump testing under identical conditions. No manual therapy is applied. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in squat jump height
Time Frame: Baseline (pre-intervention) and immediately after the intervention/rest period (approximately 15-20 minutes after baseline, same session)
|
Vertical squat jump height (cm) measured with the My Jump 2 smartphone application from high-speed video using flight time (take-off and landing frames). Best of three trials (or mean, as predefined in the protocol). Higher values indicate better jump performance. |
Baseline (pre-intervention) and immediately after the intervention/rest period (approximately 15-20 minutes after baseline, same session)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in peak hip flexion angle in the starting squat position
Time Frame: Baseline and immediately after the intervention/rest period (same session)
|
Sagittal-plane peak hip flexion angle (degrees) in the predetermined starting squat position immediately before propulsion, recorded with a Microsoft Kinect-based markerless motion analysis system; mean of three trials. |
Baseline and immediately after the intervention/rest period (same session)
|
|
Change in peak knee flexion angle in the starting squat position
Time Frame: Baseline and immediately after the intervention/rest period (same session)
|
Sagittal-plane peak knee flexion angle (degrees) in the starting squat position, Kinect-based system; mean of three trials. |
Baseline and immediately after the intervention/rest period (same session)
|
|
Change in sagittal-plane ankle, hip and knee kinematics during the squat jump
Time Frame: Baseline and immediately after the intervention/rest period (same session)
|
Composite set of sagittal-plane kinematic variables recorded with a Microsoft Kinect-based markerless motion analysis system (mean of three trials): (a) peak ankle dorsiflexion angle in the starting squat position (degrees); (b) hip, knee and ankle joint angles at the instant of take-off, defined as the last frame of foot contact (degrees); (c) hip, knee and ankle range of motion during the propulsive phase, calculated as take-off angle minus starting-position angle (degrees); and (d) peak hip, knee and ankle angular extension velocities during the propulsive phase (degrees/second), reported as exploratory given the 30 Hz sampling rate. |
Baseline and immediately after the intervention/rest period (same session)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Parsa KEİHANİ, Üsküdar University
Publications and helpful links
General Publications
- Gencoglu C, Ulupinar S, Ozbay S, Turan M, Savas BC, Asan S, Ince I. Validity and reliability of "My Jump app" to assess vertical jump performance: a meta-analytic review. Sci Rep. 2023 Nov 17;13(1):20137. doi: 10.1038/s41598-023-46935-x.
- Vieira A, Ribeiro GL, Macedo V, de Araujo Rocha Junior V, Baptista RS, Goncalves C, Cunha R, Tufano J. Evidence of validity and reliability of Jumpo 2 and MyJump 2 for estimating vertical jump variables. PeerJ. 2023 Jan 25;11:e14558. doi: 10.7717/peerj.14558. eCollection 2023.
- Franca MED, Amorim MDS, Sinhorim L, Santos GM, do Nascimento IB. Myofascial release strategies and technique recommendations for athletic performance: A systematic review. J Bodyw Mov Ther. 2023 Oct;36:30-37. doi: 10.1016/j.jbmt.2023.04.085. Epub 2023 May 10.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Uskudar31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data may be made available from the principal investigator upon reasonable request after publication of the main results.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.